Oct. 22.-24. 2022
Gürzenich, Cologne
T020 (136) Interim PET-guided treatment of early-stage nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the GHSG HD16 and HD17 studies
T021 (124) Radiation-Free Therapy as the INitial treatment of Good-prognosis early non-bulky Hodgkin lymphoma, defined by a low Metabolic Tumor Volume and a negative PET-2 - RAFTING Trial.
T022 (63) Sharing decisions regarding radiotherapy for Hodgkin lymphoma: a qualitative study of the experiences of patients and clinicians in the UK
P023 (104) PET2-adapted approach after 2 cycles of ABVD is comparable to 2 cycles of BEACOPP escalated and 2 cycles of ABVD and irradiation in early unfavorable Hodgkin lymphoma
P024 (142) Predictive Value of Baseline Metabolic Tumor Volume in Early-Stage Favorable Hodgkin Lymphoma – Data from the Prospective, Multicenter Phase III HD16 Trial
P025 (150) RADAR: An international phase III, PET response-adapted, randomised trial in progress, comparing ABVD±ISRT with brentuximab vedotin+AVD±ISRT in patients with previously untreated limited-stage classical Hodgkin lymphoma.
T064 (169) Doxorubicin exposure and breast cancer risk in adolescent and adult Hodgkin lymphoma survivors
T065 (58) Reproduction patterns among Classical Hodgkin Lymphoma Survivors Treated with BEACOPP and ABVD in Sweden, Denmark, and Norway
T066 (182) Treatment and sex-specific exposure-based risk-stratification for care of survivors of childhood Hodgkin Lymphoma: A report from the Childhood Cancer Survivor Study.
P067 (133) A pilot of lung cancer screening for survivors of Hodgkin lymphoma
P068 (157) A Retrospective Analysis of Fertility in Female Patients with Advanced Stages of Hodgkin Lymphoma Treated with BEACOPP Escalated Chemotherapy (25 Year Experience of a Single Centre)
P069 (95) Characterisation of influencing parameters on oocyte quality preservation in a cohort of Hodgkin lymphoma patients
P070 (81) Design of the INSIGHT study, evaluation of long-term follow-up care for lymphoma survivors in the Netherlands: does survivorship care at the BETER clinics reduce morbidity and mortality from late effects of lymphoma treatment and associated costs?
P071 (100) First results of cardiovascular screening in a survivorship care program for Hodgkin lymphoma survivors in the Netherlands
P072 (130) Impact of Ageing on the Survivorship Experiences of Patients with Hodgkin Lymphoma
P073 (107) Increased risk of colorectal cancer following treatment for Hodgkin lymphoma
P074 (72) Long-Term Cause-Specific Mortality in Hodgkin Lymphoma Patients – A Nationwide Danish Cohort Study
P075 (160) My Hodgkin, My Health: Feasibility of a mobile application to collect long term follow up data about Hodgkin patients.
P076 (98) Pneumococcal infection in splenectomised Hodgkin lymphoma patients: Do they pose a problem today and what is the best long-term strategy?
P077 (108) Predicting radiotherapy dose to the heart and the risk of radiation-related cardiac toxicity for Hodgkin lymphoma patients, using pre-chemotherapy PET-CT scans
P078 (106) Predicting the Health-Related Quality of Life of Hodgkin Lymphoma Survivors: Identification of Risk Factors
P079 (109) PROCTCAE as a patient-reported outcome measurement (PROM) questionaire in patients with Hodgkin Lymphoma captures different adverse events profile than those reported by physicians
P080 (64) The BETER-REFLECT Biobank: a REsource For studies on Late Effects of Cancer Treatment
P081 (118) Treatment-related circulatory diseases and mortality in Hodgkin lymphoma patients using multi-state modelling and relative survival
T082 (147) AVD - a possible golden standard in the first-line treatment of older classical Hodgkin lymphoma patients.
T083 (127) The Effect of Heart Failure on Management and Outcomes of Older Patients with Hodgkin Lymphoma
T084 (71) Treatment patterns and outcomes for Hodgkin's Lymphoma (HL) patients (pts) aged 60 and older: a report from the Brazilian Prospective Hodgkin’s lymphoma Registry
T057 (59) Circulating tumor DNA in classical Hodgkin lymphoma patients treated with pembrolizumab and chemotherapy: dynamic response assessment and correlation with baseline total metabolic tumor volume
P061 (174) Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Anti–PD-1–Naive Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
P059 (129) Multi-effector cell targeting with half-life extended bispecific scFv in Hodgkin lymphoma
P060 (167) Prognosis of patients with relapsed and refractory classic Hodgkin lymphoma after nivolumab discontinuation and efficacy of nivolumab retreatment
P062 (166) The efficacy and safety of nivolumab 40 mg therapy versus 3 mg/kg in patients with relapsed and refractory classic Hodgkin lymphoma
P063 (189) Trial in Progress: Individualized Immunotherapy in Early-Stage Unfavorable Hodgkin Lymphoma - The Investigator-Initiated Phase II GHSG INDIE Trial
T058 (179) Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti–PD-1 Treatment
T001 (134) FDG-PET and serum TARC levels after one cycle of BV-AVD in advanced stage Hodgkin lymphoma patients: results from the very early PET-response adapted EORTC-COBRA trial
T002 (193) Treatment related morbidity in patients with classical Hodgkin Lymphoma: results of the ongoing, randomized phase III HD21 Trial by The German Hodgkin Study Group
P003 (92) A retrospective study to evaluate the reliability of staging and risk stratification of adolescent and adult patients with Hodgkin’s lymphoma registered in the lymphoma clinic at Tata Memorial Centre.
P004 (80) Advanced stage classical Hodgkin lymphoma (cHL) patients with a positive interim-PET (PET-2) Deauville score (DS) 5 after 2 ABVD cycles: A pooled analysis of individual patient data of three multicenter trials
P005 (66) Age, histotype and stage IV are associated with a shorter survival in patients with Hodgkin lymphoma, even the PET-adapted era. A single center retrospective study.
P006 (135) Clinical outcome of classical Hodgkin Lymphoma patients receiving systemic anti-lymphoma treatment during SARS-COV-2 positivity: Results from the chemo-covid study on behalf of fondazione italiana linfomi
P007 (178) Comparative efficacy of the R-BEACOPP-14 and R-CHOP regimens in the treatment of patients with advanced stages of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) with THRLBCL-like histopathological growth patterns in the tumor biopsy
P008 (57) Impact of bone marrow involvement on early PET response and progression-free survival in the HD18 trial for patients with advanced-stage Hodgkin lymphoma
P009 (99) Improved Overall Survival with First-Line Brentuximab Vedotin plus Chemotherapy in Patients with Advanced Stage III/IV Classical Hodgkin Lymphoma: An Updated Analysis of ECHELON-1
P010 (121) Inferior Outcomes for Young Adults Treated on Advanced Stage Clinical Trials: Report from the HoLISTIC Consortium
P011 (188) IPS-7 or IPS-3 to identify very-high risk patients in advanced Classical Hodgkin ́s Lymphoma: Which score to choose
P012 (131) Nodular Lymphocyte-predominant Hodgkin Lymphoma a rare disease with good prognosis: a retrospective multicenter experience
P013 (103) Outcomes of first-line treatment (FL) of classical Hodgkin lymphoma (cHL) in Argentina: a real life multicenter retrospective study
P014 (186) Prognostic significance of nutritional indexes (CONUT and PNI) in classical Hodgkin lymphoma patients
P015 (94) Real World Escalated BEACOPDac Delivers Similar Outcomes to Escalated BEACOPP While Potentially Reducing Haematopoietic and Reproductive Toxicity
P016 (152) Reduced steroid exposure is safe and does not reduce disease control among Hodgkin Lymphoma patients treated with escalated BEACOPP (eBEACOPP)
P017 (187) The role of baseline bulk and dissemination measures as predictors of progression in advanced Hodgkin lymphoma.
P018 (70) Treatment outcomes in classical Hodgkin lymphoma (HL): 5-year update report from the Brazilian Prospective Registry
P019 (177) Unfavorable prognostic value of the predominance of THRLBCL-like histopathological growth patterns in nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL)
T026 (132) Characterization of cancer-associated fibroblasts in classical Hodgkin lymphoma
T027 (115) High serum levels of Thymus and Activation Related Chemokine (TARC) precede Hodgkin lymphoma diagnosis by several years
T028 (159) Single-cell RNA sequencing reveals the interplay between circulating CD4 T cells, B cells and cancer-associated monocytes in classic Hodgkin lymphoma treated with PD-1 blockade
P029 (191) Are Reed-Sternberg cells stuck in mitosis by short nucleoplasmic bridges as a consequence of centromeric instability?
P030 (172) Baseline IgM amount can identify patients with adverse outcome despite a PET-2 adapted treatment in classical Hodgkin Lymphoma: results from a real-life single-center study i
P031 (101) CD4+ T cells in close proximity to Hodgkin-Reed Sternberg cells are antigen experienced, polyclonal and display an exhausted phenotype
P032 (139) Circulating immune biomarkers in classical Hodgkin lymphoma in relation to tumor burden and response to treatment.
P033 (155) Clinical significance of the severity of THRLBCL-like areas in nodular lymphocyte predominant Hodgkin lymphoma
P034 (82) Correlation between MTV, TLG and Serum TARC Concentration in Classical Hodgkin Lymphoma during First-Line Treatment
P035 (93) CRISPR/Cas9-mediated knockout reveals an important role of CD30 in Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma
P036 (125) Detection of recurrent somatic variants in cell-free DNA as a tool for disease monitoring in Hodgkin lymphoma
P037 (137) High breadth whole exome sequencing of circulating tumor DNA identifies novel recurrent genetic alterations in Hodgkin lymphoma
P038 (117) HLA expression patterns of Hodgkin-Reed-Sternberg cells shape a spatially arranged tumor microenvironment in classical Hodgkin lymphoma
P039 (102) HLA expression status and prognostic impact of B-cell content in patients with early-stage unfavorable Hodgkin lymphoma
P040 (173) LINE-1 reverse transcriptase activity in Hodgkin lymphoma cells
P041 (74) Low percentage of T lymphocytes in Hodgkin's Lymphoma lymph nodes, measured by flow cytometry, is associated with inferior progression free survival regardless of negative interim pet scan status
P042 (185) Metabolic regulation of adaptive response to arginine deprivation in Hodgkin Lymphoma
P043 (110) Molecular pathogenesis of Hodgkin lymphoma
P044 (161) PIM kinases support protumoral and immunosuppressive phenotype and functions of macrophages in classical Hodgkin Lymphoma
P045 (79) Plasma proteome profiling of cardiotoxicity in patients with Hodgkin lymphoma
P046 (138) Preclinical evaluation of novel repurposed drug combinations in Hodgkin lymphoma
P047 (164) Predictive role of the Hodgkin lymphoma-associated cytokines: a prospective study of the Czech Hodgkin Study Group
P048 (112) Predictors of risk of relapse in classic Hodgkin lymphoma by flow cytometry
P049 (114) Reduced features of T-cell activation before and during anti-PD-1 treatment in classical Hodgkin lymphoma
P050 (168) Reed-Sternberg cells accelerate glycolytic and mitochondrial metabolism of tumor microenvironment cells
P051 (146) Serum procalcitonin levels in newly diagnosed classical Hodgkin Lymphoma (cHL): Correlation with other inflammatory biomarkers
P052 (78) Targeting CSN5/JAB1 oncogene in classical Hodgkin Lymphoma (cHL)
P053 (158) The cGAS-STING anti-tumor immune response pathway as a potential therapeutic target in classical Hodgkin Lymphoma (cHL)
P054 (86) The Kinase CK2 is deregulated and targetable in classical Hodgkin Lymphoma
P055 (111) Validation of the tumor cell-specific rearranged IgG-encoding circulating cell-free DNA for the treatment response monitoring in patients with classic Hodgkin lymphoma
P056 (156) Variants of the transcription factor ONECUT2 regulate gene expression in Hodgkin Lymphoma cells
P115 (77) Distinct signaling pathways and checkpoint molecule expression across histological subtypes of nodular lymphocyte-predominant Hodgkin lymphoma
T098 (163) Brentuximab Vedotin plus ESHAP (BRESHAP) versus ESHAP in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma. Interim Results of the BRESELIBET Prospective Clinical Trial.
T099 (149) High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma
T100 (181) Long term Follow-up of a Phase I Study Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A trial of the ECOG-ACRIN Research Group (E4412: Arms A-I)
P101 (165) Combination of immune checkpoint inhibitors with BeGEV in the treatment of patients with relapsed and refractory classical Hodgkin's lymphoma.
P102 (91) Comparison of Novel Salvage Regimens and Traditional salvage Chemotherapy in Relapsed and Refractory Classic Hodgkin Lymphoma
P103 (190) Comparison of PET-derived parameters in program cell death-1 inhibitor and CD30 antibody drug conjugate-based therapies in patients with advanced stage cHL: A single center experience.
P104 (122) Consolidation Therapy with Brentuximab Vedotin after Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma in the Czech Republic.
P105 (145) Decisional role of interim PET in relapsed/refractory classical Hodgkin Lymphoma treated with four begev cycles
P106 (140) Dose intensive brentuximab vedotin for platinum resistant recurrent Hodgkin lymphoma is a feasible treatment option - a single center experience
P107 (105) Effect of Brentuximab Vedotin Addition to Chemotherapy and Prognostic Factors in Patients with Relapsed/Refractory Hodgkin Lymphoma: a Large Multi-Trial Analysis Based on Individual Patient Data
P108 (183) Integrating baseline circulating tumor DNA with interim PET improves outcome prediction in relapsed/refractory classical Hodgkin lymphoma
P109 (180) One-Day Brentuximab-Bendamustine (120mg/m2) every 21 days is a feasible and safe treatment for relapsed/refractory Hodgkin lymphoma
P110 (88) Outcome of high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT) as first salvage treatment for relapsed or refractory classical Hodgkin Lymphoma (cHL) in the era of PET-adapted strategy among Italian centers
P111 (143) Phase I Trial of Brentuximab Vedotin plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma
P112 (162) Phase II Trial of Brentuximab Vedotin plus ibrutinib in Relapsed/Refractory Hodgkin Lymphoma
P113 (154) Promising results with anti-PD-1 therapy in primary refractory Hodgkin lymphoma: a single-centre report
P114 (126) Very late relapses in patients with Hodgkin Lymphoma occuring ≥5 years after initial treament with chemotherapy ± radiotherapy: Treatment strategies and prognostic factors for the outcome
P091 (148) Early analysis of the PRO-Hodgkin study: Clinical investigation of pencil beam scanning proton treatment in Hodgkin lymphoma patients.
P092 (113) Estimating the dosimetric benefit of involved-node radiotherapy in comparison to involved-field radiotherapy - implications from the GHSG HD 17 trial
P093 (55) From involved- field to involved-node – Quality analysis of the radiation therapy in HD 17 by the expert panel of the German Hodgkin Study Group
P094 (83) Long-term outcomes of bulky classic Hodgkin lymphoma managed with a PET-adapted approach demonstrate excellent outcomes in PET-negative cases
P095 (85) Personalised Modelling of Quality-Adjusted Survival Benefit and Cost-Effectiveness of using Proton Beam Therapy inthe Treatment of Intermediate-Stage Hodgkin Lymphoma in England
P096 (89) Polymorphisms in SETD7 may predispose the risk of developing late cardiac side effects after radiotherapy including the mediastinum in Hodgkin´s lymphoma.
P097 (54) The status quo of involved-field radiotherapy – Quality analysis of radiotherapy in the GHSG HD 16
P086 (116) Advancing Pediatric Hodgkin Lymphoma Research Through NODAL
P088 (76) Case series of Nodular Lymphocyte Predominant Hodgkin Lymphoma from Tanzania. A common entity in East Africa?
P089 (171) Pembrolizumab in Pediatric and Young Adults Patients With Newly Diagnosed Classical Hodgkin Lymphoma and Slow Early Responders to Frontline Chemotherapy: The Phase 2 KEYNOTE-667 Study
P090 (144) Staging of Lung Lesions Survey Demonstrates Continued Need for Harmonization
T087 (96) Brentuximab vedotin (Bv) Demonstrates Superior Event-Free Survival in Pediatric High-Risk Hodgkin Lymphoma
Gürzenich Cologne Martinstraße 29-37 50677 Cologne During the Conference the Secretariat can be contacted at Phone: +49 (0) 173 939 07 30 Email: info@tca-hanke.de
Saturday, 22.10.2018 07:00–18:00 Sunday, 23.10.2018 07:00–19:00 Monday, 24.10.2018 07:00–18:00
For accomodation support, please contact the conference management: Phone: +49 (0) 2102 669 36 Email: info@tca-hanke.de
Please make sure to always wear your badge at the conference. If you lose your badge, we will have to charge you a replacement fee.
During the breaks, complimentary coffee, fruit and refreshments will be available.
The cloakroom is located in the basement.
The conference language is English.
The meeting organizers cannot accept liability for personal injuries sustained to Conference participants or for loss or damage of their personal belongings, neither during nor as a result of the meeting.
There will be free WIFI at the Gürzenich Conference Center. Further details and access codes will be provided on site. You can also use the two on-site internet terminals for web browsing and web-based email access.
Pre-registration will close on October 21, 2022. All registrations received on or after October 22 will be considered as on-site registrations and will be charged the on-site fee. Full registration will include access to the scientific sessions and exhibition, a copy of the program, the welcome reception on Saturday (October 22) and all refreshment breaks. You will also receive a name tag; please wear this name tag at all conference events including the scientific symposia. No refunds will be given.
The Speakers Ready Room is located next to the registration desk on the ground floor of the Gürzenich Conference Center. Speakers are requested to hand in their PowerPoint presentations in 16:9 format saved on a stick at least 3 hours before their session or the day before if the session starts early in the morning. We can only accept Windows PowerPoint files for upload to the conference system. It is not permitted to use your own laptops or other devices for uploading the files.
Please note that there will be a strict non-smoking policy at all conference facilities.
On Saturday evening, the conference will be opened officially. After the Opening Ceremony, all participants are warmly invited to join us at our Get Together event at the Gürzenich Conference Center. This event is a great opportunity to meet and chat with many colleagues involved in Hodgkin Lymphoma research and treatment. Drinks and snacks will be provided.
A nondenominational prayer room will be available in the conference center. For further details, please contact the Conference Secretariat.
The 12th International Symposium on Hodgkin Lymphoma is certified by the European Board for Accreditation in Hematology (formerly EHA) with 35 EBAH credit points. Please collect your certificates before departure at the registration desk (in the entrance hall of the Gürzenich)
The airports closest to Cologne City are Cologne Bonn Airport (CGN; 15 km) and Düsseldorf Airport (DUS; 45 km). From Cologne Bonn Airport you can reach Cologne central station by regional rail in about 30 minutes; from Frankfurt Airport to Cologne it takes only an hour by InterCity Express (ICE) and from Düsseldorf Airport about 45 minutes. Cologne central station is within walking distance (about 10 minutes) from the Gürzenich Conference Center and the Dorint Hotel. You can also take bus no. 132 and get off at “Gürzenichstraße”. The other hotels recommended by the Conference Organization can easily be reached by public transport. Cologne has an efficient public transport system, but the recommended hotels, the venue as well as other places of interest are within a comfortable walking distance from each other. For those who are traveling by car, we recommend to use the parking ground “Heumarkt” (about 3 minutes walking distance from the Gürzenich). If you want to take a taxi, you can either get in directly at one of the numerous taxi stands or you can order a taxi by phone from one of the taxi call centers (+49 221 170000 or +49 221 2882). Uber and Lyft or other ride sharing services do not operate reliably in Cologne or are not available at all. A taxi will most of the time be the better option.
On Saturday evening, the conference will be opened officially. After the Opening Ceremony, all participants are warmly invited to join us at our Get Together event at the Gürzenich Conference Center. This event is a great opportunity to meet and chat with many colleagues involved in Hodgkin Lymphoma research and treatment. Drinks and snacks will be provided.
We wish to express our appreciation and gratitude to our partners.
ERN-EuroBloodNet's main goal is to improve the healthcare and overall quality of life of patients with a Rare Hematological Disease.
Certified by the European Board for Accreditation in Hematology (EBAH) with 35 EBAH credit points.
Prof. Dr. Andreas Engert German Hodgkin Study Group (GHSG) Gleueler Str. 269-273 50935 Köln Phone: +49 (0)221-478 5933 Fax: +49 (0)221-478 3778
In accordance with the German Act for Telemedia Services (TMG), § 55 Abs. 2 RStV (section 55, subsection 2 broadcast services state treaty): Prof. Dr. Andreas Engert
Legal Entitiy: The University Hospital of Cologne is a Public Law Institution. Legal Representation: The University Hospital of Cologne is represented by the Board of Directors, in turn represented by: Prof. Dr. Edgar Schömig, CEO and medical director Günter Zwilling, Director of finance Kerpener Str. 62 D-50937 Köln